Immutep Advances First-in-Human Phase I Study of IMP761 to Dose Escalation Phase
    Immutep Advances First-in-Human Phase I Study of IMP761 to Dose Escalation Phase
    PRISM Biotech

    October 18, 2024  - by Editor Prism MarketView

    Immutep Advances First-in-Human Phase I Study of IMP761 to Dose Escalation Phase

    18 October 2024

    New York, October 18, 2024 - PRISM MarketView - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company focused on LAG-3 immunotherapies, announced that its first-in-human Phase I study of IMP761 has progressed to the dose escalation phase. The study, conducted at the Centre for Human Drug Research (CHDR) in the Netherlands, involves administering increasing doses of IMP761 to healthy volunteers after the successful completion of the initial single-dose phase without safety concerns. IMP761, a novel immunosuppressive LAG-3 agonist antibody, aims to target the underlying cause of autoimmune diseases by silencing autoimmune memory T cells. First safety data is expected by the end of 2024, with additional pharmacokinetic and pharmacodynamic assessments anticipated in the first half of 2025.

    Immutep Limited - Prism MarketView

    When our Chief Scientific Officer, Dr. Frédéric Triebel, first discovered Lymphocyte Activation Gene-3 (LAG-3), he realized there was a novel pathway that cou

    Read More

    About Immutep
    Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.
    To see this content properly accept cookies.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    To see this content properly accept cookies.
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.